Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALO-001
- Development stage
- Preclinical
- Lead developer
- Alleo Labs
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ALO-001 is an orally administered small-molecule drug in preclinical development by Alleo Labs for neurodegenerative indications, including Parkinson’s disease and Alzheimer’s disease, with a proposed mechanism as a deubiquitinating enzyme inhibitor targeting neuroinflammation and proteostasis pathways.[3]
- Other names
- ALO 001ALO001ALO-001
02
Targets
DUB (Deubiquitinases)
Beyond the preview
Go deeper on ALO-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALO-001.